MADISON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Wyeth (NYSE:WYE)
announced today that the jury in the case of Gloria Ann Stribling v. Wyeth,
in New Jersey State Court in Hackensack (Bergen County), found in favor of
the plaintiff and assessed total damages of $3 million. Wyeth is reviewing
its post-trial options.
"We respectfully disagree with the jury's finding and believe it is
unsupported by the evidence, which demonstrated that Mrs. Stribling's
health problems were caused by her severe, longstanding obstructive sleep
apnea and not the diet drugs she took more than 10 years ago," says Steve
Reade, an attorney from Arnold & Porter, who represented Wyeth. "The
evidence also demonstrated that the drug labels were adequate, and that
changes to those labels would have made no difference to Mrs. Stribling or
her doctors."
The trial began on September 22, 2008 before The Honorable Robert
Polifroni. The plaintiff alleged primary pulmonary hypertension (PPH)
caused by her use of the diet drug Pondimin, a drug once marketed by Wyeth.
In an earlier stage of the proceedings, the Court ruled that plaintiff
could not pursue punitive damages in this case.
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery,
development, manufacturing and marketing of pharmaceuticals, vaccines,
biotechnology products, nutritionals and non-prescription medicines that
improve the quality of life for people worldwide. The Company's major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort
Dodge Animal Health.
SOURCE Wyeth
 back to top
Related links:
http://www.wyeth.com
CONTACT:
Media, Douglas Petkus, +1-973-660-5218, or
Investor, Justin Victoria, +1-973-660-5340, both of Wyeth
|
